VolitionRx (NYSE:VNRX) Stock Rating Reaffirmed by Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of VolitionRx (NYSE:VNRX) in a research report released on Wednesday morning, Benzinga reports. The brokerage currently has a $2.50 price objective on the stock.

VolitionRx Stock Performance

Shares of VNRX opened at $0.76 on Wednesday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.69 and a current ratio of 0.69. The company has a market capitalization of $62.13 million, a price-to-earnings ratio of -1.48 and a beta of 1.38. The company’s 50 day simple moving average is $0.98 and its 200 day simple moving average is $0.87. VolitionRx has a 1 year low of $0.55 and a 1 year high of $2.10.

VolitionRx (NYSE:VNRX) last announced its quarterly earnings data on Monday, March 25th. The company reported ($0.11) earnings per share (EPS) for the quarter. The firm had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $0.50 million. VolitionRx had a negative net margin of 4,557.29% and a negative return on equity of 7,185.73%. On average, sell-side analysts predict that VolitionRx will post -0.39 EPS for the current year.

Hedge Funds Weigh In On VolitionRx

An institutional investor recently bought a new position in VolitionRx stock. Silverberg Bernstein Capital Management LLC purchased a new position in shares of VolitionRx Limited (NYSE:VNRX) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 147,038 shares of the company’s stock, valued at approximately $105,000. Silverberg Bernstein Capital Management LLC owned about 0.19% of VolitionRx as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening blood test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.